Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC

Abstract

Introduction: Capmatinib, a MET inhibitor, showed substantial antitumour activ-ity with manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. We report patient -reported outcomes (PROs) from this study.Methods: Enrolled treatment-naive (1L) or pre-treated (2L thorn ) patients with aNSCLC with a METex14-skipping mutation received 400 mg capmatinib twice daily during 21-day treatment cycles. PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L vi-sual analogue scale (VAS) questionnaires.Results: As of 6 January 2020, 27/28 1L and 65/69 2L thorn patients had completed PROs at base-line; compliance rates remained >70%. Cough improved early, with meaningful improvements (>10-point change from baseline) observed throughout cycles (mean change from baseline [SD] by week 7: 1L-13.0 [39.9], 2L+-8.2 [28.4]; week 43: 1L-28.2 [26.7], 2L+-10.5 [27.3]). QoL, assessed by GHS/QoL and VAS, improved by week 7 in 1L and 2L+ patients, with improvements generally sustained over time. Median time to definitive deterioration (TTDD) in GHS/QoL was 16.6 months (95% CI: 9.7, not estimable [NE]) in 1L and 12.4 months (95% CI: 4.2, 19.4) in 2L+ patients. Median TTDD for dyspnoea was 19.4 months (95% CI: 12.4, NE) and 22.1 months (95% CI: 9.9, NE) for 1L and 2L+ patients, respectively, and NE for cough and chest pain. Conclusions: Capmatinib was associated with clinically meaningful improvements in cough and preserved QoL, further supporting its use in patients with METex14-mutated aNSCLC.Trial registration: ClinicalTrials.gov registry number: NCT02414139. 2022 Published by Elsevier Ltd.